UK markets closed

Allarity Therapeutics A/S (ALLR.ST)

Stockholm - Stockholm Real-time price. Currency in SEK
Add to watchlist
1.7070+0.0420 (+2.52%)
At close: 5:29PM CEST
Full screen
Previous close1.6650
Open1.7280
Bid1.6810 x N/A
Ask1.7000 x N/A
Day's range1.6500 - 1.7280
52-week range0.6134 - 2.5500
Volume2,555,668
Avg. volume15,290,340
Market cap665.838M
Beta (5Y monthly)0.65
PE ratio (TTM)N/A
EPS (TTM)-0.6410
Earnings date28 Aug 2020
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Allarity Therapeutics and Lonza Collaborate to Manufacture Dovitinib, a Renal Cell Carcinoma Candidate

    Integrated solution for process development and manufacturing of drug substance and drug product will facilitate the advancement of clinical developmentThe agreement meets Allarity’s needs for current and future commercial production of dovitinib and will support the Company’s planned NDA filing in 2021 Basel, Switzerland and Hoersholm, Denmark, 23 September 2021 – Allarity Therapeutics A/S, a clinical-stage precision medicine company actively advancing a pipeline of in-licensed oncology therape

  • Globe Newswire

    Allarity Therapeutics Presents Dovitinib Survival Data from DRP® Screened RCC Patients at ESMO 2021 Virtual Congress

    Patient selection using DRP® score of 50% resulted in a median survival of 15.0 monthPatient selection using DRP® score of 67% resulted in a median survival of 20.6 months Press Release Hørsholm, Denmark (September 16, 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced validation results for its Dovitinib DRP® companion diagnostic utilizing data from Novartis’ prior Phase III trial of dovitinib in renal cell carcinoma (RCC), which will be included in a poster present

  • Globe Newswire

    Update: Allarity Therapeutics Receives Approximately SEK 23.3 Million (US $2.7 Million) from Subscription to Warrants of Series ALLR TO 2 and TO 3

    Subscription is approximately 9.5 percent of total outstanding TO 3 warrants Allarity’s Chairman of the Board and largest shareholder (Sass & Larsen ApS) participated in the subscription Press ReleaseHørsholm, Denmark (September 15, 2021) CORRECTION: The press release that the company published on September 14, 2021, at 23:06 CEST, contained an incomplete computation of the number of subscribed shares. The correct number of subscribed shares shall be 13,719,266. Consequently, the amount raised i